Physician profile
Layron Omar Long
NPI 1649382417
$14,628.12
in general payments reported to CMS, 2019-2025
31 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $3.82 · 2021: $930 · 2022: $331 · 2023: $11K · 2024: $617 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $1,960 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Gift: $28.95 · Education: $16.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,677.85 |
| Food and Beverage | $1,959.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Gift | $28.95 |
| Education | $16.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu A/S | $9,777.85 | 2023 | |
| Intuitive Surgical, INC. | $1,195.81 | 2021-2024 | Da Vinci Sp |
| Ambu INC. | $1,049.10 | 2023-2025 | |
| Boston Scientific Corporation | $594.05 | 2019-2025 | Lithovue, Rezum Generator, Axonics |
| Lazarus 3d | $573.04 | 2022-2025 | Pre-Sure |
| Abbvie INC. | $265.44 | 2021-2025 | |
| Laborie Medical Technologies Corp. | $131.83 | 2021-2023 | |
| Urogen Pharma, INC. | $122.80 | 2024-2025 | |
| Procept Biorobotics Corporation | $106.14 | 2022-2025 | |
| Accord Healthcare, INC. | $95.24 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $84.90 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Conmed Corporation | $83.37 | 2021 | |
| Myriad Genetic Laboratories, INC. | $60.73 | 2021-2023 | Prolaris |
| Pfizer INC. | $60.72 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $59.55 | 2023-2024 | Orgovyx, Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $47.24 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $33.22 | 2019 | |
| Allergan, INC. | $33.03 | 2019 | |
| Astellas Pharma US INC | $29.64 | 2022-2023 | Myrbetriq |
| Janssen Biotech, INC. | $27.52 | 2019 | |
| Medtronic USA, INC. | $26.00 | 2019 | |
| Angiodynamics, INC. | $21.71 | 2024 | Nanoknife |
| Baxter Healthcare | $21.66 | 2025 | Tisseel |
| Edwards Lifesciences Corporation | $19.81 | 2023 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $19.19 | 2024 | |
| Ethicon US, LLC | $18.43 | 2019 | |
| Photocure INC | $17.60 | 2023 | Cysview |
| Verity Pharmaceuticals INC. | $14.52 | 2024 | Trelstar |
| Axonics, INC. | $13.68 | 2023 | Axonics, Bulkamid |
| Karl Storz Endoscopy-America | $12.84 | 2022 | |
| Travere Therapeutics, INC. | $11.46 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layron Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.